OTCMKTS:KSPHF Kissei Pharmaceutical (KSPHF) Stock Price, News & Analysis $24.50 0.00 (0.00%) As of 10/23/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartNews and Trends About Kissei Pharmaceutical Stock (OTCMKTS:KSPHF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kissei Pharmaceutical alerts:Sign Up Key Stats Today's Range$24.50▼$24.5050-Day Range$24.50▼$25.7752-Week Range$23.23▼$31.90VolumeN/AAverage Volume563 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Kissei Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacture and marketing of prescription medicines and related healthcare products. The company focuses primarily on therapeutic areas including urology, gastroenterology, nephrology, gynecology and metabolic disorders. Kissei develops and commercializes medicines for conditions such as overactive bladder, urinary disorders and gastrointestinal diseases. Its activities include drug discovery, clinical development, manufacturing and the distribution of pharmaceutical products through Japan’s healthcare system. Founded in 1946 and headquartered in Matsumoto, Nagano, Kissei Pharmaceutical serves the Japanese market and pursues international activities through overseas subsidiaries, licensing arrangements and partnerships. The company also conducts research collaborations intended to expand its product pipeline and support the development of treatments in its specialized therapeutic fields.AI Generated. May Contain Errors. Read More Receive KSPHF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kissei Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KSPHF Stock News HeadlinesKissei Pharmaceutical Reports Progress on Share Buyback ProgramSeptember 3, 2026 | tipranks.comKissei Pharmaceutical Posts Mixed Q1 Results, Lifts Dividends but Cuts FY2027 OutlookAugust 15, 2026 | theglobeandmail.comManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.October 28 at 1:00 AM | Monument Traders Alliance (Ad)Jefferies Sticks to Their Buy Rating for Kissei Pharmaceutical Co (KSPHF)May 5, 2026 | theglobeandmail.comKissei Launches Yselty in Japan, Expanding Global Uterine Fibroid Treatment PortfolioMarch 21, 2026 | theglobeandmail.comKissei Pharmaceutical Co (KSPHF) Receives a Buy from DaiwaJanuary 31, 2026 | theglobeandmail.comKissei Pharmaceutical initiated with a neutral at UBSDecember 14, 2025 | msn.comKissei Pharmaceutical Adjusts Dividend Payment DateDecember 1, 2025 | tipranks.comSee More Headlines KSPHF Stock Analysis - Frequently Asked Questions How have KSPHF shares performed this year? Kissei Pharmaceutical's stock was trading at $26.97 at the beginning of 2026. Since then, KSPHF stock has decreased by 9.2% and is now trading at $24.50. How do I buy shares of Kissei Pharmaceutical? Shares of KSPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/28/2026Next Earnings (Estimated)11/04/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:KSPHF CIKN/A Webwww.kissei.co.jp Phone(126) 325-9081FaxN/AEmployees1,786Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (OTCMKTS:KSPHF) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kissei Pharmaceutical Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kissei Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
